Structured evidence table for Berberine Lipid Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Berberine Lipid Meta-Analysis | Berberine lowers both lipids and glucose, yet its role on cardiometabolic disease risk remain unclear. | 2 | Zhao JV (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization. |
| Berberine Lipid Meta-Analysis | Based on a randomized controlled trial of berberine (registered in ClinicalTrials.gov on Dec 2018, NCT03770325), leveraging proteomics and sex hormones data, we built a signature reflecting response to berberine using elastic net regression. | 2 | Zhao JV (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization. |
| Berberine Lipid Meta-Analysis | The primary prevention of CVD through the management of dyslipidemia, a major risk factor for CVD, is a critical strategy for improving population health outcomes and reducing the associated economic impact. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
| Berberine Lipid Meta-Analysis | Statin use has increased substantially in recent years, with nearly two-thirds of those taking statins for primary prevention. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
| Berberine Lipid Meta-Analysis | The clinical guidelines also recommend statin use among people previously considered at low risk of CVD. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
| Berberine Lipid Meta-Analysis | 1 2 4 – 5 6 , 7 4 8 10 ,– 11 12 13 16 – Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide, which poses a heavy burden on healthcare. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
Source documents